Psychemedics Corporation Announces Third Quarter Profits
DECLARES 57th CONSECUTIVE QUARTERLY DIVIDEND
ACTON, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced third quarter financial results for the period ended September 30, 2010. The Company also announced a quarterly dividend of $0.12 per share payable to shareholders of record as of November 26, 2010 to be paid on December 10, 2010. This will be the Company's 57th consecutive quarterly dividend.
The Company's revenue for the quarter ended September 30, 2010 was $5.1 million versus $4.7 million for the quarter ended September 30, 2009, an increase of 9%. Net income for the quarter ended September 30, 2010 was $817 thousand or $0.16 per share, versus $768 thousand or $0.15 per share, for the comparable period last year. The Company's revenue for the nine months ended September 30, 2010 was $15.0 million, as compared to $12.7 million for the comparable period of 2009. Net income for the nine months ended September 30, 2010 was $2.2 million or $0.42 per diluted share, as compared to last year during which the Company earned $981 thousand or $0.19 per diluted share.
Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "We are pleased to report increased revenues and profits in the third quarter over last year's Q3 results. We did, however, experience a slowdown in the rate of revenue growth compared to the second quarter rate of growth, reflecting the economic uncertainty that characterized this third quarter. However, our revenue growth of over 9% and our earnings per share increase, from $0.15 vs. $0.16, represent very solid results. We were also pleased that we were able to produce a 26% pre-tax profit margin. We remain confident about our future prospects."
Kubacki concluded, "We continue to have a strong balance sheet with more than $4.8 million in cash, cash equivalents and short-term investments and no long term debt. Our directors share our confidence in the long-term future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we move forward. Therefore, we are pleased to declare our 57th consecutive quarterly dividend. The quarterly dividend will be $0.12 per share."
Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.
The Psychemedics web site is www.drugtestwithhair.com
Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.
PSYCHEMEDICS CORPORATION | ||||||||
STATEMENTS OF INCOME | ||||||||
UNAUDITED | ||||||||
3 Months Ended | 9 Months Ended | |||||||
September 30, | September 30, | September 30, | September 30, | |||||
2010 | 2009 | 2010 | 2009 | |||||
Revenues | $5,106,262 | $4,669,894 | $14,992,625 | $12,683,654 | ||||
Cost of revenues | 2,080,214 | 1,779,732 | 6,033,093 | 5,595,740 | ||||
Gross Profit | 3,026,048 | 2,890,162 | 8,959,532 | 7,087,914 | ||||
Operating expenses: | ||||||||
General & administrative | 850,312 | 862,518 | 2,760,195 | 2,784,379 | ||||
Marketing & selling | 722,815 | 643,139 | 2,098,192 | 2,325,538 | ||||
Research & development | 116,534 | 111,402 | 364,445 | 353,965 | ||||
Total operating expenses | 1,689,661 | 1,617,059 | 5,222,832 | 5,463,882 | ||||
Operating income | 1,336,387 | 1,273,103 | 3,736,700 | 1,624,032 | ||||
Interest income | 4,940 | 11,576 | 19,422 | 34,166 | ||||
Net income before provision for income taxes | 1,341,327 | 1,284,679 | 3,756,122 | 1,658,198 | ||||
Provision for income taxes | 523,959 | 516,373 | 1,559,391 | 676,986 | ||||
Net income | $817,368 | $768,306 | $2,196,731 | $981,212 | ||||
Basic net income per share | $0.16 | $0.15 | $0.42 | $0.19 | ||||
Diluted net income per share | $0.16 | $0.15 | $0.42 | $0.19 | ||||
Dividends declared per share | $0.12 | $0.12 | $0.36 | $0.41 | ||||
Weighted average common shares outstanding, basic | 5,212,835 | 5,178,545 | 5,205,480 | 5,182,504 | ||||
Weighted average common shares outstanding, diluted | 5,228,378 | 5,184,061 | 5,219,760 | 5,194,118 | ||||
PSYCHEMEDICS CORPORATION | ||||
BALANCE SHEETS | ||||
UNAUDITED | ||||
September 30, | December 31, | |||
2010 | 2009 | |||
ASSETS | ||||
Current Assets: | ||||
Cash and cash equivalents | $2,872,960 | $4,840,367 | ||
Short-term investments | 2,017,407 | 1,006,436 | ||
Accounts receivable, net of allowance for doubtful accounts | 4,335,593 | 3,016,084 | ||
of 86,400 in 2010 and 134,282 in 2009 | ||||
Prepaid expenses | 697,226 | 573,191 | ||
Other current assets | 168,681 | 90,242 | ||
Deferred tax assets | 304,994 | 253,221 | ||
Total Current Assets | 10,396,861 | 9,779,541 | ||
Fixed Assets: | ||||
Equipment & leasehold improvements | 11,320,800 | 10,912,906 | ||
Less accumulated depreciation | (10,585,459) | (10,381,599) | ||
Net Fixed Assets | 735,341 | 531,307 | ||
Deferred tax asset, long term | 204,764 | 204,764 | ||
Other assets | 84,927 | 86,814 | ||
Total Assets | $11,421,893 | $10,602,426 | ||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||
Current Liabilities: | ||||
Accounts payable | $361,389 | $180,784 | ||
Accrued expenses | 743,040 | 759,067 | ||
Accrued income taxes | 413,699 | 331,831 | ||
Deferred revenue | 16,515 | 36,360 | ||
Total Current Liabilities | 1,534,643 | 1,308,042 | ||
Commitments and Contingencies | ||||
Shareholders' Equity: | ||||
Preferred-stock, $0.005 par value, 872,521 shares authorized, | - | - | ||
no shares issued or outstanding | ||||
Common stock, $0.005 par value, 50,000,000 shares authorized, | 29,387 | 29,309 | ||
5,877,358 shares issued in 2010 and 5,861,872 shares issued in 2009 | ||||
Paid-in capital | 27,690,178 | 27,419,359 | ||
Less - Treasury stock, at cost, 664,523 shares in 2010 and 2009 | (10,053,364) | (10,053,364) | ||
Accumulated deficit | (7,778,951) | (8,100,920) | ||
Total Shareholders' Equity | 9,887,250 | 9,294,384 | ||
Total Liabilities & Shareholders' Equity | $11,421,893 | $10,602,426 | ||
SOURCE Psychemedics Corporation
Share this article